Cargando…

Hyperlipidemia in immune thrombocytopenia: a retrospective study

BACKGROUND: Immune thrombocytopenia (ITP) is an autoimmune hemorrhagic disease characterized by low platelet count and bleeding manifestations. However, some patients also suffered from atherosclerosis or even infarction. Apart from activated platelets, lipid metabolism takes a large part in the for...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Shouqing, Lu, Hui, Yu, Yafei, Liu, Xinguang, Jing, Fangmiao, Wang, Liang, Zhao, Yajing, Hou, Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10544441/
https://www.ncbi.nlm.nih.gov/pubmed/37784127
http://dx.doi.org/10.1186/s12959-023-00545-9
_version_ 1785114505078898688
author Han, Shouqing
Lu, Hui
Yu, Yafei
Liu, Xinguang
Jing, Fangmiao
Wang, Liang
Zhao, Yajing
Hou, Ming
author_facet Han, Shouqing
Lu, Hui
Yu, Yafei
Liu, Xinguang
Jing, Fangmiao
Wang, Liang
Zhao, Yajing
Hou, Ming
author_sort Han, Shouqing
collection PubMed
description BACKGROUND: Immune thrombocytopenia (ITP) is an autoimmune hemorrhagic disease characterized by low platelet count and bleeding manifestations. However, some patients also suffered from atherosclerosis or even infarction. Apart from activated platelets, lipid metabolism takes a large part in the formation of atherosclerosis and metabolic syndrome. The lipid metabolic state in ITP patients is still unknown. METHODS: We retrospectively reviewed 302 hospitalized ITP patients in our cohort, comparing their blood lipids, bleeding symptoms, metabolic diseases and treatment responses. RESULTS: We found a high proportion of ITP patients suffered from hyperlipidemia, and other metabolic diseases including cardiovascular or cerebral atherosclerosis or infarction, hypertension, and type 2 diabetes. Hyperlipidemia was associated with severe bleeding and treatment refractoriness in ITP. Statins could alleviate thrombocytopenia and bleeding severity, and facilitate ITP treatment, while improving hyperlipidemia in ITP patients. CONCLUSIONS: Our present study demonstrated that lipid metabolism might play an indispensable role in ITP pathogenesis and development. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12959-023-00545-9.
format Online
Article
Text
id pubmed-10544441
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-105444412023-10-03 Hyperlipidemia in immune thrombocytopenia: a retrospective study Han, Shouqing Lu, Hui Yu, Yafei Liu, Xinguang Jing, Fangmiao Wang, Liang Zhao, Yajing Hou, Ming Thromb J Research BACKGROUND: Immune thrombocytopenia (ITP) is an autoimmune hemorrhagic disease characterized by low platelet count and bleeding manifestations. However, some patients also suffered from atherosclerosis or even infarction. Apart from activated platelets, lipid metabolism takes a large part in the formation of atherosclerosis and metabolic syndrome. The lipid metabolic state in ITP patients is still unknown. METHODS: We retrospectively reviewed 302 hospitalized ITP patients in our cohort, comparing their blood lipids, bleeding symptoms, metabolic diseases and treatment responses. RESULTS: We found a high proportion of ITP patients suffered from hyperlipidemia, and other metabolic diseases including cardiovascular or cerebral atherosclerosis or infarction, hypertension, and type 2 diabetes. Hyperlipidemia was associated with severe bleeding and treatment refractoriness in ITP. Statins could alleviate thrombocytopenia and bleeding severity, and facilitate ITP treatment, while improving hyperlipidemia in ITP patients. CONCLUSIONS: Our present study demonstrated that lipid metabolism might play an indispensable role in ITP pathogenesis and development. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12959-023-00545-9. BioMed Central 2023-10-02 /pmc/articles/PMC10544441/ /pubmed/37784127 http://dx.doi.org/10.1186/s12959-023-00545-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Han, Shouqing
Lu, Hui
Yu, Yafei
Liu, Xinguang
Jing, Fangmiao
Wang, Liang
Zhao, Yajing
Hou, Ming
Hyperlipidemia in immune thrombocytopenia: a retrospective study
title Hyperlipidemia in immune thrombocytopenia: a retrospective study
title_full Hyperlipidemia in immune thrombocytopenia: a retrospective study
title_fullStr Hyperlipidemia in immune thrombocytopenia: a retrospective study
title_full_unstemmed Hyperlipidemia in immune thrombocytopenia: a retrospective study
title_short Hyperlipidemia in immune thrombocytopenia: a retrospective study
title_sort hyperlipidemia in immune thrombocytopenia: a retrospective study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10544441/
https://www.ncbi.nlm.nih.gov/pubmed/37784127
http://dx.doi.org/10.1186/s12959-023-00545-9
work_keys_str_mv AT hanshouqing hyperlipidemiainimmunethrombocytopeniaaretrospectivestudy
AT luhui hyperlipidemiainimmunethrombocytopeniaaretrospectivestudy
AT yuyafei hyperlipidemiainimmunethrombocytopeniaaretrospectivestudy
AT liuxinguang hyperlipidemiainimmunethrombocytopeniaaretrospectivestudy
AT jingfangmiao hyperlipidemiainimmunethrombocytopeniaaretrospectivestudy
AT wangliang hyperlipidemiainimmunethrombocytopeniaaretrospectivestudy
AT zhaoyajing hyperlipidemiainimmunethrombocytopeniaaretrospectivestudy
AT houming hyperlipidemiainimmunethrombocytopeniaaretrospectivestudy